Literature DB >> 10627107

Alcoholics Anonymous and the use of medications to prevent relapse: an anonymous survey of member attitudes.

R G Rychtarik1, G J Connors, K H Dermen, P R Stasiewicz.   

Abstract

OBJECTIVE: The purpose of this study was to systematically assess the attitudes of Alcoholics Anonymous (AA) members toward the newer medications used to prevent relapse (e.g., naltrexone) and to assess their experiences with medication use, of any type, in AA.
METHOD: Using media solicitations and snowball sampling techniques, 277 AA members were surveyed anonymously about their attitudes toward use of medication for preventing relapse and their experiences with medication use of any type in AA.
RESULTS: Over half the sample believed the use of relapse-preventing medication either was a good idea or might be a good idea. Only 17% believed an individual should not take it and only 12% would tell another member to stop taking it. Members attending relatively more meetings in the past 3 months had less favorable attitudes toward the medication. Almost a third (29%) reported personally experiencing some pressure to stop a medication (of any type). However, 69% of these continued taking the medication.
CONCLUSIONS: The study did not find strong, widespread negative attitudes toward medication for preventing relapse among AA members. Nevertheless, some discouragement of medication use does occur in AA. Though most AA members apparently resist pressure to stop a medication, when medication is prescribed a need exists to integrate it within the philosophy of 12-step treatment programs.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10627107     DOI: 10.15288/jsa.2000.61.134

Source DB:  PubMed          Journal:  J Stud Alcohol        ISSN: 0096-882X


  14 in total

Review 1.  Choosing a behavioral therapy platform for pharmacotherapy of substance users.

Authors:  Kathleen M Carroll; Thomas R Kosten; Bruce J Rounsaville
Journal:  Drug Alcohol Depend       Date:  2004-08-16       Impact factor: 4.492

2.  Organizational-level predictors of adoption across time: naltrexone in private substance-use disorders treatment centers.

Authors:  Carrie B Oser; Paul M Roman
Journal:  J Stud Alcohol Drugs       Date:  2007-11       Impact factor: 2.582

3.  Attitudes toward opioid use disorder medications: Results from a U.S. national study of individuals who resolved a substance use problem.

Authors:  Brandon G Bergman; Robert D Ashford; John F Kelly
Journal:  Exp Clin Psychopharmacol       Date:  2019-09-26       Impact factor: 3.157

4.  Service utilization during and after outpatient treatment for comorbid substance use disorder and depression.

Authors:  Matthew J Worley; Ryan S Trim; Susan R Tate; Jessica E Hall; Sandra A Brown
Journal:  J Subst Abuse Treat       Date:  2010-07-03

Review 5.  Improving the care of individuals with schizophrenia and substance use disorders: consensus recommendations.

Authors:  Douglas M Ziedonis; David Smelson; Richard N Rosenthal; Steven L Batki; Alan I Green; Renata J Henry; Ivan Montoya; Joseph Parks; Roger D Weiss
Journal:  J Psychiatr Pract       Date:  2005-09       Impact factor: 1.325

6.  Treatment choices and subsequent attendance by substance-dependent patients who disengage from intensive outpatient treatment.

Authors:  Deborah H A Van Horn; Michelle Drapkin; Kevin G Lynch; Lior Rennert; Jessica D Goodman; Tyrone Thomas; Megan Ivey; James R McKay
Journal:  Addict Res Theory       Date:  2015-04-22

7.  12-step affiliation and attendance following treatment for comorbid substance dependence and depression: a latent growth curve mediation model.

Authors:  Matthew J Worley; Susan R Tate; John R McQuaid; Eric L Granholm; Sandra A Brown
Journal:  Subst Abus       Date:  2013       Impact factor: 3.716

8.  Adoption of injectable naltrexone in U.S. substance use disorder treatment programs.

Authors:  Lydia Aletraris; Mary Bond Edmond; Paul M Roman
Journal:  J Stud Alcohol Drugs       Date:  2015-01       Impact factor: 2.582

9.  Impact of research network participation on the adoption of buprenorphine for substance abuse treatment.

Authors:  Traci R Rieckmann; Amanda J Abraham; Anne E Kovas; Bentson H McFarland; Paul M Roman
Journal:  Addict Behav       Date:  2014-02-07       Impact factor: 3.913

10.  Response: the marriage of drug abuse treatment and 12-step strategies.

Authors:  Robert R Forman; Keith Humphreys; J Scott Tonigan
Journal:  Sci Pract Perspect       Date:  2003-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.